Advances in therapy for chronic hepatitis B

Seminars in Liver Disease

Volumn 22, Issue SUPPL. 1, 2002, Pages 33-36

  Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Adefovir dipivoxil; Adenine analogues and derivatives therapeutic use; Antiviral agents; Chronic hepatitis B; Drug resistance; Hepatitis B virus drug effects

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS MUTANT;

EID: 0036434602     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35698     Document Type: Review

References (16)

1. World Health Organization. Hepatitis B Fact Sheet. Geneva, Switzerland: WHO; 2000. Available at: http://www.who.int/inf-fs/en/fact204.htm (accessed June 04, 2002)
2. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241
3. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356
4. de Man RA, Marcellin P, Habal F, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000;32:413-417
5. Marcellin P, Chang T-T, Lim SG, et al. GS-98-437. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 Week results. Hepatology 2001;34:340A
6. Marcellin P, Goodman Z, Chang T-T, et al. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
7. Hadziyannis S, Tassopoulos N, Heathcote J, et al. GS-98-438. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 Week results. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
8. Liaw Y-F, Leung NWY, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
9. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
10. Leung NWY, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532
11. Chang TT, Liaw YF, Guan R, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antivir Ther 2000;5(Suppl 1):44 (Abst)
12. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 Week interim analysis. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
13. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306
14. Benhamou Y, Bochet M,Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-723
15. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
16. Schiff E, Neuhaus P, Tillmann H, et al. Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAMR) in post liver transplant (post-OLT) patients. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)